Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial.
Tobias KesslerDaniel SchrimpfLaura DörnerLing HaiLeon D KaulenJakob ItoMartin J Van Den BentMartin J B TaphoornAlba Ariela BrandesAhmed IdbaïhJulien DômontPaul M J ClementMario CamponeMartin BendszusAndreas von DeimlingFelix SahmMichael PlattenWolfgang WickAntje WickPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Thorough molecular classification is important for brain tumor clinical trial inclusion and evaluation. MGMT promoter methylation and RTK1 classifier assignment were prognostic in progressive glioblastoma. NF1 mutation may be a predictive biomarker for bevacizumab treatment.
Keyphrases
- dna methylation
- clinical trial
- multiple sclerosis
- genome wide
- phase ii
- gene expression
- study protocol
- phase iii
- machine learning
- signaling pathway
- deep learning
- open label
- oxidative stress
- lps induced
- randomized controlled trial
- transcription factor
- immune response
- nuclear factor
- copy number
- pi k akt
- metastatic colorectal cancer